GLP1 Medication	Title of Article	PubMed Link (clickable)
DULAGLUTIDE	Effects of dulaglutide on alcohol consumption during smoking cessation	https://pubmed.ncbi.nlm.nih.gov/37991022
DULAGLUTIDE	A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design	https://pubmed.ncbi.nlm.nih.gov/37245533
DULAGLUTIDE	Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis	https://pubmed.ncbi.nlm.nih.gov/36897834
DULAGLUTIDE	Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/36894938
DULAGLUTIDE	Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial	https://pubmed.ncbi.nlm.nih.gov/36781064
DULAGLUTIDE	Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial	https://pubmed.ncbi.nlm.nih.gov/36771262
DULAGLUTIDE	Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/36755915
DULAGLUTIDE	Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/36316432
DULAGLUTIDE	Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial	https://pubmed.ncbi.nlm.nih.gov/36073143
DULAGLUTIDE	Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/35658022
DULAGLUTIDE	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial	https://pubmed.ncbi.nlm.nih.gov/35043140
DULAGLUTIDE	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial	https://pubmed.ncbi.nlm.nih.gov/34984808

GLP1 Medication	Title of Article	PubMed Link (clickable)
DULAGLUTIDE	Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study	https://pubmed.ncbi.nlm.nih.gov/34787823
DULAGLUTIDE	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND	https://pubmed.ncbi.nlm.nih.gov/34563178
DULAGLUTIDE	Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11	https://pubmed.ncbi.nlm.nih.gov/34463420
DULAGLUTIDE	Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11	https://pubmed.ncbi.nlm.nih.gov/34189841
DULAGLUTIDE	Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial	https://pubmed.ncbi.nlm.nih.gov/34159708
DULAGLUTIDE	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial	https://pubmed.ncbi.nlm.nih.gov/34153269
DULAGLUTIDE	Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/33675117
DULAGLUTIDE	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial	https://pubmed.ncbi.nlm.nih.gov/33537745
DULAGLUTIDE	Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)	https://pubmed.ncbi.nlm.nih.gov/33397768
DULAGLUTIDE	Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial	https://pubmed.ncbi.nlm.nih.gov/33397395
DULAGLUTIDE	Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis	https://pubmed.ncbi.nlm.nih.gov/35373017
DULAGLUTIDE	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin	https://pubmed.ncbi.nlm.nih.gov/33197271

GLP1 Medication	Title of Article	PubMed Link (clickable)
EXENATIDE	Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37974132
EXENATIDE	The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus	https://pubmed.ncbi.nlm.nih.gov/37773814
EXENATIDE	Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/37214201
EXENATIDE	The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/36894921
EXENATIDE	Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study	https://pubmed.ncbi.nlm.nih.gov/36843215
EXENATIDE	The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial	https://pubmed.ncbi.nlm.nih.gov/36244997
EXENATIDE	Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms	https://pubmed.ncbi.nlm.nih.gov/35859471
EXENATIDE	Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT	https://pubmed.ncbi.nlm.nih.gov/35829765
EXENATIDE	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)	https://pubmed.ncbi.nlm.nih.gov/35761271
EXENATIDE	Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/35725020
EXENATIDE	FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/35723225
EXENATIDE	Once-Weekly Exenatide in Youth With Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/35679098

GLP1 Medication	Title of Article	PubMed Link (clickable)
EXENATIDE	Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide	https://pubmed.ncbi.nlm.nih.gov/35600575
EXENATIDE	Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/35491524
EXENATIDE	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial	https://pubmed.ncbi.nlm.nih.gov/35484607
EXENATIDE	Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial	https://pubmed.ncbi.nlm.nih.gov/35403350
EXENATIDE	Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study	https://pubmed.ncbi.nlm.nih.gov/35217772
EXENATIDE	Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/35134184
EXENATIDE	Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials	https://pubmed.ncbi.nlm.nih.gov/34939100
EXENATIDE	Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/34873344
EXENATIDE	Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women	https://pubmed.ncbi.nlm.nih.gov/34867786
EXENATIDE	Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome	https://pubmed.ncbi.nlm.nih.gov/34732660
EXENATIDE	Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial	https://pubmed.ncbi.nlm.nih.gov/34625598
EXENATIDE	Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes	https://pubmed.ncbi.nlm.nih.gov/34617375
EXENATIDE	Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study)	https://pubmed.ncbi.nlm.nih.gov/34142743

GLP1 Medication	Title of Article	PubMed Link (clickable)
EXENATIDE	Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome	https://pubmed.ncbi.nlm.nih.gov/34097062
EXENATIDE	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus	https://pubmed.ncbi.nlm.nih.gov/33905751
EXENATIDE	Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin	https://pubmed.ncbi.nlm.nih.gov/33831552
EXENATIDE	Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study	https://pubmed.ncbi.nlm.nih.gov/33687487
EXENATIDE	Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers	https://pubmed.ncbi.nlm.nih.gov/33576936
EXENATIDE	The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study	https://pubmed.ncbi.nlm.nih.gov/33495294
EXENATIDE	Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial	https://pubmed.ncbi.nlm.nih.gov/33464703
EXENATIDE	High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/33452595
LIRAGLUTIDE	Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial	https://pubmed.ncbi.nlm.nih.gov/37696925
LIRAGLUTIDE	Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/37672063
LIRAGLUTIDE	A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity	https://pubmed.ncbi.nlm.nih.gov/37626125

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome	https://pubmed.ncbi.nlm.nih.gov/37567946
LIRAGLUTIDE	Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/37494014
LIRAGLUTIDE	Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial	https://pubmed.ncbi.nlm.nih.gov/37349083
LIRAGLUTIDE	Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial	https://pubmed.ncbi.nlm.nih.gov/37264767
LIRAGLUTIDE	Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes	https://pubmed.ncbi.nlm.nih.gov/37188932
LIRAGLUTIDE	[Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity]	https://pubmed.ncbi.nlm.nih.gov/37150681
LIRAGLUTIDE	Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?	https://pubmed.ncbi.nlm.nih.gov/37093453
LIRAGLUTIDE	Potential contributors to variation in weight-loss response to liraglutide	https://pubmed.ncbi.nlm.nih.gov/37069131
LIRAGLUTIDE	Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37036569
LIRAGLUTIDE	Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis	https://pubmed.ncbi.nlm.nih.gov/36963632
LIRAGLUTIDE	The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies	https://pubmed.ncbi.nlm.nih.gov/36910413
LIRAGLUTIDE	Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial	https://pubmed.ncbi.nlm.nih.gov/36883362

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs	https://pubmed.ncbi.nlm.nih.gov/36820578
LIRAGLUTIDE	Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility	https://pubmed.ncbi.nlm.nih.gov/36781820
LIRAGLUTIDE	Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update	https://pubmed.ncbi.nlm.nih.gov/36771035
LIRAGLUTIDE	Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)	https://pubmed.ncbi.nlm.nih.gov/36722623
LIRAGLUTIDE	A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects	https://pubmed.ncbi.nlm.nih.gov/36648126
LIRAGLUTIDE	Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea	https://pubmed.ncbi.nlm.nih.gov/36542275
LIRAGLUTIDE	Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/36314246
LIRAGLUTIDE	Factors associated with successful weight loss after liraglutide treatment for obesity	https://pubmed.ncbi.nlm.nih.gov/36193713
LIRAGLUTIDE	Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/36180402
LIRAGLUTIDE	Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study	https://pubmed.ncbi.nlm.nih.gov/36093105
LIRAGLUTIDE	Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats	https://pubmed.ncbi.nlm.nih.gov/36038016
LIRAGLUTIDE	Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China	https://pubmed.ncbi.nlm.nih.gov/35990242

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis	https://pubmed.ncbi.nlm.nih.gov/35936066
LIRAGLUTIDE	Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial	https://pubmed.ncbi.nlm.nih.gov/35894080
LIRAGLUTIDE	Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial	https://pubmed.ncbi.nlm.nih.gov/35868334
LIRAGLUTIDE	Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia	https://pubmed.ncbi.nlm.nih.gov/35833597
LIRAGLUTIDE	Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome	https://pubmed.ncbi.nlm.nih.gov/35751892
LIRAGLUTIDE	Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study	https://pubmed.ncbi.nlm.nih.gov/35710599
LIRAGLUTIDE	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial	https://pubmed.ncbi.nlm.nih.gov/35415938
LIRAGLUTIDE	A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)	https://pubmed.ncbi.nlm.nih.gov/35382966
LIRAGLUTIDE	Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin	https://pubmed.ncbi.nlm.nih.gov/35378386
LIRAGLUTIDE	A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg	https://pubmed.ncbi.nlm.nih.gov/35285173
LIRAGLUTIDE	Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss	https://pubmed.ncbi.nlm.nih.gov/35277168
LIRAGLUTIDE	Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study	https://pubmed.ncbi.nlm.nih.gov/35263425

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections	https://pubmed.ncbi.nlm.nih.gov/35101325
LIRAGLUTIDE	Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study	https://pubmed.ncbi.nlm.nih.gov/34996406
LIRAGLUTIDE	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride	https://pubmed.ncbi.nlm.nih.gov/34920733
LIRAGLUTIDE	Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/34918951
LIRAGLUTIDE	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial	https://pubmed.ncbi.nlm.nih.gov/34917038
LIRAGLUTIDE	Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide	https://pubmed.ncbi.nlm.nih.gov/34882926
LIRAGLUTIDE	Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population	https://pubmed.ncbi.nlm.nih.gov/34797962
LIRAGLUTIDE	Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study	https://pubmed.ncbi.nlm.nih.gov/34737187
LIRAGLUTIDE	[The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus]	https://pubmed.ncbi.nlm.nih.gov/34689519
LIRAGLUTIDE	Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME)	https://pubmed.ncbi.nlm.nih.gov/34622567
LIRAGLUTIDE	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes	https://pubmed.ncbi.nlm.nih.gov/34595827
LIRAGLUTIDE	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/34535716

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/34518158
LIRAGLUTIDE	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/34463425
LIRAGLUTIDE	The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis	https://pubmed.ncbi.nlm.nih.gov/34455568
LIRAGLUTIDE	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial	https://pubmed.ncbi.nlm.nih.gov/34387408
LIRAGLUTIDE	Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial	https://pubmed.ncbi.nlm.nih.gov/34358471
LIRAGLUTIDE	Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/34252552
LIRAGLUTIDE	A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review	https://pubmed.ncbi.nlm.nih.gov/34209532
LIRAGLUTIDE	Effect of Liraglutide on Arterial Inflammation Assessed as [(18)F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial	https://pubmed.ncbi.nlm.nih.gov/34187185
LIRAGLUTIDE	Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study	https://pubmed.ncbi.nlm.nih.gov/34172436
LIRAGLUTIDE	Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials	https://pubmed.ncbi.nlm.nih.gov/34139800
LIRAGLUTIDE	Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i	https://pubmed.ncbi.nlm.nih.gov/34132018
LIRAGLUTIDE	Role of liraglutide in Alzheimer's disease pathology	https://pubmed.ncbi.nlm.nih.gov/34118986
LIRAGLUTIDE	Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review	https://pubmed.ncbi.nlm.nih.gov/34052248

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/34012064
LIRAGLUTIDE	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined	https://pubmed.ncbi.nlm.nih.gov/33951361
LIRAGLUTIDE	Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies	https://pubmed.ncbi.nlm.nih.gov/33934692
LIRAGLUTIDE	Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide	https://pubmed.ncbi.nlm.nih.gov/33822469
LIRAGLUTIDE	Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial	https://pubmed.ncbi.nlm.nih.gov/33662334
LIRAGLUTIDE	Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/33650779
LIRAGLUTIDE	Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial	https://pubmed.ncbi.nlm.nih.gov/33634589
LIRAGLUTIDE	Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes	https://pubmed.ncbi.nlm.nih.gov/33624417
LIRAGLUTIDE	Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge	https://pubmed.ncbi.nlm.nih.gov/33591621
LIRAGLUTIDE	Liraglutide Does Not Adversely Impact Fat-Free Mass Loss	https://pubmed.ncbi.nlm.nih.gov/33528919
LIRAGLUTIDE	Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/33471039
LIRAGLUTIDE	Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study	https://pubmed.ncbi.nlm.nih.gov/33413428

GLP1 Medication	Title of Article	PubMed Link (clickable)
LIRAGLUTIDE	Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/33309563
LIRAGLUTIDE	Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management	https://pubmed.ncbi.nlm.nih.gov/33272167
LIRAGLUTIDE	Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/33140542
LIRAGLUTIDE	Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial	https://pubmed.ncbi.nlm.nih.gov/33099848
LIRAGLUTIDE	Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction	https://pubmed.ncbi.nlm.nih.gov/32867644
LIRAGLUTIDE	Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study	https://pubmed.ncbi.nlm.nih.gov/32656729
LIRAGLUTIDE	The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial	https://pubmed.ncbi.nlm.nih.gov/32107930
SEMAGLUTIDE	Efficacy and safety of semaglutide in non-alcoholic fatty liver disease	https://pubmed.ncbi.nlm.nih.gov/37899788
SEMAGLUTIDE	Semaglutide: a new drug for the treatment of obesity	https://pubmed.ncbi.nlm.nih.gov/37879878
SEMAGLUTIDE	Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37717295
SEMAGLUTIDE	Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)	https://pubmed.ncbi.nlm.nih.gov/37659049

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study)	https://pubmed.ncbi.nlm.nih.gov/37646192
SEMAGLUTIDE	Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity	https://pubmed.ncbi.nlm.nih.gov/37622681
SEMAGLUTIDE	Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity	https://pubmed.ncbi.nlm.nih.gov/37605636
SEMAGLUTIDE	Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37498865
SEMAGLUTIDE	Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/37455913
SEMAGLUTIDE	[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP]	https://pubmed.ncbi.nlm.nih.gov/37448249
SEMAGLUTIDE	Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial	https://pubmed.ncbi.nlm.nih.gov/37385279
SEMAGLUTIDE	Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/37385278
SEMAGLUTIDE	Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial	https://pubmed.ncbi.nlm.nih.gov/37364590
SEMAGLUTIDE	Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial	https://pubmed.ncbi.nlm.nih.gov/37328931
SEMAGLUTIDE	Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/37301063

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	https://pubmed.ncbi.nlm.nih.gov/37294245
SEMAGLUTIDE	Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/37265222
SEMAGLUTIDE	Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg	https://pubmed.ncbi.nlm.nih.gov/37196421
SEMAGLUTIDE	Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review	https://pubmed.ncbi.nlm.nih.gov/37189293
SEMAGLUTIDE	Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial	https://pubmed.ncbi.nlm.nih.gov/37062189
SEMAGLUTIDE	The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials	https://pubmed.ncbi.nlm.nih.gov/37055712
SEMAGLUTIDE	Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial	https://pubmed.ncbi.nlm.nih.gov/36945734
SEMAGLUTIDE	Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial	https://pubmed.ncbi.nlm.nih.gov/36934740
SEMAGLUTIDE	Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects	https://pubmed.ncbi.nlm.nih.gov/36932262
SEMAGLUTIDE	Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial	https://pubmed.ncbi.nlm.nih.gov/36905345
SEMAGLUTIDE	Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial	https://pubmed.ncbi.nlm.nih.gov/36876594
SEMAGLUTIDE	Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/36871874

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial	https://pubmed.ncbi.nlm.nih.gov/36871272
SEMAGLUTIDE	Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study	https://pubmed.ncbi.nlm.nih.gov/36765019
SEMAGLUTIDE	Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial	https://pubmed.ncbi.nlm.nih.gov/36746803
SEMAGLUTIDE	Efficacy and safety of semaglutide for weight management: evidence from the STEP program	https://pubmed.ncbi.nlm.nih.gov/36691309
SEMAGLUTIDE	Cardiometabolic risk factors efficacy of semaglutide in the STEP program	https://pubmed.ncbi.nlm.nih.gov/36691308
SEMAGLUTIDE	Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program	https://pubmed.ncbi.nlm.nih.gov/36691307
SEMAGLUTIDE	Integrating semaglutide into obesity management - a primary care perspective	https://pubmed.ncbi.nlm.nih.gov/36691306
SEMAGLUTIDE	Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5	https://pubmed.ncbi.nlm.nih.gov/36655300
SEMAGLUTIDE	The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease	https://pubmed.ncbi.nlm.nih.gov/36651820
SEMAGLUTIDE	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations	https://pubmed.ncbi.nlm.nih.gov/36601368
SEMAGLUTIDE	Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis	https://pubmed.ncbi.nlm.nih.gov/36578889
SEMAGLUTIDE	Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	https://pubmed.ncbi.nlm.nih.gov/36534451
SEMAGLUTIDE	Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics	https://pubmed.ncbi.nlm.nih.gov/36502289
SEMAGLUTIDE	Semaglutide for the treatment of overweight and obesity: A review	https://pubmed.ncbi.nlm.nih.gov/36254579
SEMAGLUTIDE	Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	https://pubmed.ncbi.nlm.nih.gov/36216945
SEMAGLUTIDE	Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity	https://pubmed.ncbi.nlm.nih.gov/36121652

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/35838946
SEMAGLUTIDE	Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial	https://pubmed.ncbi.nlm.nih.gov/35791625
SEMAGLUTIDE	Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis	https://pubmed.ncbi.nlm.nih.gov/35709586
SEMAGLUTIDE	The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials	https://pubmed.ncbi.nlm.nih.gov/35684020
SEMAGLUTIDE	The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs	https://pubmed.ncbi.nlm.nih.gov/35653929
SEMAGLUTIDE	Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes	https://pubmed.ncbi.nlm.nih.gov/35623229
SEMAGLUTIDE	Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6	https://pubmed.ncbi.nlm.nih.gov/35582947
SEMAGLUTIDE	Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial	https://pubmed.ncbi.nlm.nih.gov/35546450
SEMAGLUTIDE	In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk	https://pubmed.ncbi.nlm.nih.gov/35500264
SEMAGLUTIDE	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6	https://pubmed.ncbi.nlm.nih.gov/35484580
SEMAGLUTIDE	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension	https://pubmed.ncbi.nlm.nih.gov/35441470
SEMAGLUTIDE	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial	https://pubmed.ncbi.nlm.nih.gov/35439567
SEMAGLUTIDE	Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting	https://pubmed.ncbi.nlm.nih.gov/35344191

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India	https://pubmed.ncbi.nlm.nih.gov/35245858
SEMAGLUTIDE	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation	https://pubmed.ncbi.nlm.nih.gov/35226299
SEMAGLUTIDE	Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity	https://pubmed.ncbi.nlm.nih.gov/35175229
SEMAGLUTIDE	Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index	https://pubmed.ncbi.nlm.nih.gov/35174649
SEMAGLUTIDE	Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial	https://pubmed.ncbi.nlm.nih.gov/35131037
SEMAGLUTIDE	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials	https://pubmed.ncbi.nlm.nih.gov/35112504
SEMAGLUTIDE	Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/35015037
SEMAGLUTIDE	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/34993760
SEMAGLUTIDE	Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis	https://pubmed.ncbi.nlm.nih.gov/34981419
SEMAGLUTIDE	Clinical review of subcutaneous semaglutide for obesity	https://pubmed.ncbi.nlm.nih.gov/34964141
SEMAGLUTIDE	Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/34957654
SEMAGLUTIDE	Semaglutide for the treatment of obesity	https://pubmed.ncbi.nlm.nih.gov/34942372
SEMAGLUTIDE	An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression	https://pubmed.ncbi.nlm.nih.gov/34922383
SEMAGLUTIDE	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER	https://pubmed.ncbi.nlm.nih.gov/34903039

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials	https://pubmed.ncbi.nlm.nih.gov/34894326
SEMAGLUTIDE	[Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)]	https://pubmed.ncbi.nlm.nih.gov/34881835
SEMAGLUTIDE	Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/34866313
SEMAGLUTIDE	Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics	https://pubmed.ncbi.nlm.nih.gov/34728099
SEMAGLUTIDE	Wegovy (semaglutide): a new weight loss drug for chronic weight management	https://pubmed.ncbi.nlm.nih.gov/34706925
SEMAGLUTIDE	High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management	https://pubmed.ncbi.nlm.nih.gov/34706581
SEMAGLUTIDE	Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials	https://pubmed.ncbi.nlm.nih.gov/34622548
SEMAGLUTIDE	Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/34622228
SEMAGLUTIDE	Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?	https://pubmed.ncbi.nlm.nih.gov/34576096
SEMAGLUTIDE	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging	https://pubmed.ncbi.nlm.nih.gov/34570916
SEMAGLUTIDE	Semaglutide (Wegovy) for weight loss	https://pubmed.ncbi.nlm.nih.gov/34543259
SEMAGLUTIDE	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss	https://pubmed.ncbi.nlm.nih.gov/34514682
SEMAGLUTIDE	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials	https://pubmed.ncbi.nlm.nih.gov/34472698
SEMAGLUTIDE	Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis	https://pubmed.ncbi.nlm.nih.gov/34468297
SEMAGLUTIDE	Safety of Semaglutide	https://pubmed.ncbi.nlm.nih.gov/34305810

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial	https://pubmed.ncbi.nlm.nih.gov/34293304
SEMAGLUTIDE	Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial	https://pubmed.ncbi.nlm.nih.gov/34289755
SEMAGLUTIDE	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide	https://pubmed.ncbi.nlm.nih.gov/34267725
SEMAGLUTIDE	Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation	https://pubmed.ncbi.nlm.nih.gov/34248838
SEMAGLUTIDE	Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials	https://pubmed.ncbi.nlm.nih.gov/34024887
SEMAGLUTIDE	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/33964002
SEMAGLUTIDE	The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis	https://pubmed.ncbi.nlm.nih.gov/33960005
SEMAGLUTIDE	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial	https://pubmed.ncbi.nlm.nih.gov/33894838
SEMAGLUTIDE	A Review on the Efficacy and Safety of Oral Semaglutide	https://pubmed.ncbi.nlm.nih.gov/33772451
SEMAGLUTIDE	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/33755728
SEMAGLUTIDE	Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/33710717
SEMAGLUTIDE	Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/33667417

GLP1 Medication	Title of Article	PubMed Link (clickable)
SEMAGLUTIDE	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/33625476
SEMAGLUTIDE	Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects	https://pubmed.ncbi.nlm.nih.gov/33591618
SEMAGLUTIDE	Once-Weekly Semaglutide in Adults with Overweight or Obesity	https://pubmed.ncbi.nlm.nih.gov/33567185
SEMAGLUTIDE	Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/33434602
SEMAGLUTIDE	Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial	https://pubmed.ncbi.nlm.nih.gov/33419635
SEMAGLUTIDE	The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review	https://pubmed.ncbi.nlm.nih.gov/33317348
SEMAGLUTIDE	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis	https://pubmed.ncbi.nlm.nih.gov/33185364
SEMAGLUTIDE	Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/33184979
SEMAGLUTIDE	Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial	https://pubmed.ncbi.nlm.nih.gov/33159658
SEMAGLUTIDE	Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/33108617
SEMAGLUTIDE	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial	https://pubmed.ncbi.nlm.nih.gov/33074557
SEMAGLUTIDE	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?	https://pubmed.ncbi.nlm.nih.gov/32826189

GLP1 Medication	Title of Article	PubMed Link (clickable)
TIRZEPATIDE	In adults with BMI ≥27 kg/m(2) and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk	https://pubmed.ncbi.nlm.nih.gov/37931265
TIRZEPATIDE	Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37908750
TIRZEPATIDE	Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis	https://pubmed.ncbi.nlm.nih.gov/37904345
TIRZEPATIDE	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/37840095
TIRZEPATIDE	Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4	https://pubmed.ncbi.nlm.nih.gov/37824793
TIRZEPATIDE	Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/37786396
TIRZEPATIDE	Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial	https://pubmed.ncbi.nlm.nih.gov/37700443
TIRZEPATIDE	The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/37621649
TIRZEPATIDE	Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis	https://pubmed.ncbi.nlm.nih.gov/37606127
TIRZEPATIDE	Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?	https://pubmed.ncbi.nlm.nih.gov/37552101
TIRZEPATIDE	The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide	https://pubmed.ncbi.nlm.nih.gov/37551549
TIRZEPATIDE	Beyond glycemia: Comparing tirzepatide to GLP-1 analogues	https://pubmed.ncbi.nlm.nih.gov/37526853
TIRZEPATIDE	Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials	https://pubmed.ncbi.nlm.nih.gov/37460681

GLP1 Medication	Title of Article	PubMed Link (clickable)
TIRZEPATIDE	Effect of the Dual Glucose-Dependent Insulinotropic Peptide/Gulcagon-like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37455226
TIRZEPATIDE	Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/37385275
TIRZEPATIDE	A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/37285081
TIRZEPATIDE	Perspectives on weight control in diabetes - Tirzepatide	https://pubmed.ncbi.nlm.nih.gov/37279858
TIRZEPATIDE	Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/37253796
TIRZEPATIDE	Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial	https://pubmed.ncbi.nlm.nih.gov/37231074
TIRZEPATIDE	Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach	https://pubmed.ncbi.nlm.nih.gov/37208555
TIRZEPATIDE	Tirzepatide and potential use for metabolically healthy obesity	https://pubmed.ncbi.nlm.nih.gov/37183081
TIRZEPATIDE	Weight loss efficiency and safety of tirzepatide: A Systematic review	https://pubmed.ncbi.nlm.nih.gov/37141329
TIRZEPATIDE	Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/37096236
TIRZEPATIDE	Tirzepatide: Clinical review of the "twincretin" injectable	https://pubmed.ncbi.nlm.nih.gov/37070418
TIRZEPATIDE	A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?	https://pubmed.ncbi.nlm.nih.gov/37051199
TIRZEPATIDE	An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program	https://pubmed.ncbi.nlm.nih.gov/36908082
TIRZEPATIDE	Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/36857477
TIRZEPATIDE	Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	https://pubmed.ncbi.nlm.nih.gov/36820516
TIRZEPATIDE	Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?	https://pubmed.ncbi.nlm.nih.gov/36688833

GLP1 Medication	Title of Article	PubMed Link (clickable)
TIRZEPATIDE	Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/36516422
TIRZEPATIDE	Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies	https://pubmed.ncbi.nlm.nih.gov/36514843
TIRZEPATIDE	Tirzepatide: A Systematic Update	https://pubmed.ncbi.nlm.nih.gov/36498958
TIRZEPATIDE	Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program	https://pubmed.ncbi.nlm.nih.gov/36478180
TIRZEPATIDE	Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist	https://pubmed.ncbi.nlm.nih.gov/36375235
TIRZEPATIDE	Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice	https://pubmed.ncbi.nlm.nih.gov/36367094
TIRZEPATIDE	Tirzepatide-Friend or Foe in Diabetic Cancer Patients?	https://pubmed.ncbi.nlm.nih.gov/36358930
TIRZEPATIDE	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity	https://pubmed.ncbi.nlm.nih.gov/36313764
TIRZEPATIDE	Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials	https://pubmed.ncbi.nlm.nih.gov/36274410
TIRZEPATIDE	Tirzepatide: A New Generation Therapeutic for Diabetes Type 2	https://pubmed.ncbi.nlm.nih.gov/36200219
TIRZEPATIDE	Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)	https://pubmed.ncbi.nlm.nih.gov/36184780
TIRZEPATIDE	Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/36152639
TIRZEPATIDE	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction	https://pubmed.ncbi.nlm.nih.gov/36050763
TIRZEPATIDE	[Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes]	https://pubmed.ncbi.nlm.nih.gov/36004653

GLP1 Medication	Title of Article	PubMed Link (clickable)
TIRZEPATIDE	Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide	https://pubmed.ncbi.nlm.nih.gov/35977865
TIRZEPATIDE	Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective	https://pubmed.ncbi.nlm.nih.gov/35929488
TIRZEPATIDE	Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/35914543
TIRZEPATIDE	Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/35914542
TIRZEPATIDE	Tirzepatide Trial Demonstrates Substantial Weight Loss	https://pubmed.ncbi.nlm.nih.gov/35881126
TIRZEPATIDE	Tirzepatide: First Approval	https://pubmed.ncbi.nlm.nih.gov/35830001
TIRZEPATIDE	Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review	https://pubmed.ncbi.nlm.nih.gov/35807558
TIRZEPATIDE	Tirzepatide to treat obesity: phase III results	https://pubmed.ncbi.nlm.nih.gov/35773392
TIRZEPATIDE	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health	https://pubmed.ncbi.nlm.nih.gov/35767712
TIRZEPATIDE	Tirzepatide Once Weekly for the Treatment of Obesity	https://pubmed.ncbi.nlm.nih.gov/35658024
TIRZEPATIDE	Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP	https://pubmed.ncbi.nlm.nih.gov/35651477
TIRZEPATIDE	Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/35593668
TIRZEPATIDE	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/35579691
TIRZEPATIDE	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial	https://pubmed.ncbi.nlm.nih.gov/35468325
TIRZEPATIDE	Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial	https://pubmed.ncbi.nlm.nih.gov/35468322

GLP1 Medication	Title of Article	PubMed Link (clickable)
TIRZEPATIDE	Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial	https://pubmed.ncbi.nlm.nih.gov/35468321
TIRZEPATIDE	Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/35459459
TIRZEPATIDE	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis	https://pubmed.ncbi.nlm.nih.gov/35210595
TIRZEPATIDE	Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/35133415
TIRZEPATIDE	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/34672967
TIRZEPATIDE	A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes	https://pubmed.ncbi.nlm.nih.gov/34647404
TIRZEPATIDE	Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/34608929
TIRZEPATIDE	The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis	https://pubmed.ncbi.nlm.nih.gov/34542221
TIRZEPATIDE	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/34370970
TIRZEPATIDE	Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial	https://pubmed.ncbi.nlm.nih.gov/34186022
TIRZEPATIDE	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/34170647
TIRZEPATIDE	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide	https://pubmed.ncbi.nlm.nih.gov/33778934

GLP1 Medication	Title of Article	PubMed Link (clickable)
TIRZEPATIDE	Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes	https://pubmed.ncbi.nlm.nih.gov/33236115